aTyr Pharma, Inc. (FRA:471A)
Germany · Delayed Price · Currency is EUR | Market Cap | 37.30M -88.8% |
| Revenue (ttm) | 164.79K -19.1% |
| Net Income | -60.74M |
| EPS | -0.63 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.3110 |
| Previous Close | 0.3070 |
| Day's Range | 0.3110 - 0.3110 |
| 52-Week Range | 0.2510 - 5.7000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About aTyr Pharma
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pn... [Read more]
Financial Performance
In 2025, aTyr Pharma's revenue was $190,000, a decrease of -19.15% compared to the previous year's $235,000. Losses were -$74.12 million, 15.8% more than in 2024.
Financial numbers in USD Financial StatementsNews
aTyr Pharma Transcript: Jefferies Global Healthcare Conference 2026
Efzofitimod showed strong, durable benefits in pulmonary sarcoidosis, especially for restrictive patients, with significant improvements in quality of life and lung function. A new phase III trial will focus on FVC as the primary endpoint, targeting a high-need population and leveraging increased drug exposure for greater efficacy.
Forget the SpaceX IPO. These 2 New Stocks Stand Out Right Now.
Recent IPOs Pattern Group and Ethos Technologies are showing constructive technical patterns even as investors continue waiting for a SpaceX public offering.
Ethos Partners with Baseball Legend David Ortiz to Champion Life Insurance as a Family Financial Essential
AUSTIN, Texas, May 21, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a new partnership with baseball...
aTyr Pharma upgraded to Buy from Hold at Freedom Broker
Freedom Broker upgraded aTyr Pharma (ATYR) to Buy from Hold with a price target of $3.50, up from $1. The firm says much of the uncertainty following the EFZO-FIT study…
Ethos to Present at Upcoming Investor Conferences
AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ: LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder a...
aTyr Pharma reports Q1 EPS (11c), consensus (15c)
“2026 is off to a productive start, as we now have a clear path forward for efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease, following our recent…
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patient...
aTyr Pharma Quarterly report: Q1 2026
aTyr Pharma has published its Q1 2026 quarterly earnings report on May 15, 2026.
aTyr Pharma Earnings release: Q1 2026
aTyr Pharma released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Ethos Announces Early Lock-Up Release
AUSTIN, Texas--(BUSINESS WIRE)--Ethos Announces Early Lock-Up Release.
aTyr Pharma to Participate in Upcoming Investor Conferences
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its propr...
aTyr Pharma provides regulatory update on efzofitimod following Type C meeting
aTyr Pharma (ATYR) announced the path forward for efzofitimod, in pulmonary sarcoidosis, following the receipt of the official meeting minutes from a Type C meeting with the FDA. The purpose…
aTyr Pharma Transcript: Study update
A new phase III trial for efzofitimod in pulmonary sarcoidosis will focus on patients with restrictive lung disease, using FVC as the primary endpoint and an optimized dosing schedule. The study aims to enroll 372 patients globally, targeting a multi-billion dollar market opportunity.
aTyr Pharma Press release: Study update
aTyr Pharma issued a press release on May 11, 2026, disclosing material business information to investors.
aTyr Pharma Slides: Study update
aTyr Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chron...
Ethos Reports First Quarter Fiscal Year 2026 Financial Results
Q1 Revenue grew 104% year-over-year to $193 million Q1 Direct Channel Revenue grew 136% year-over-year to $146 million Q1 Third-Party Revenue grew 42% year-over-year to $47 million AUSTIN, Texas, May ...
Ethos Launches ChatGPT App To Bring Instant Life Insurance Estimates to 900 Million Users
AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ: LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announce...
Ethos Collaborates with Liberty Mutual to Deliver a Modern, Digital-First Life Insurance Experience
500 - Internal server error. Server Error 500 - Internal server error.
Ethos to Announce First Quarter 2026 Financial Results on May 6, 2026
AUSTIN, Texas, April 02, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ: LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announ...
aTyr Pharma Proxy statement: Proxy filing
aTyr Pharma filed a proxy statement on March 26, 2026, providing details for shareholder voting and corporate governance matters.
aTyr Pharma Proxy statement: Proxy filing
aTyr Pharma filed a proxy statement on March 26, 2026, providing details for shareholder voting and corporate governance matters.
Ethos and Banner Life Expand Offering to Bring Final Expense Coverage to More Families
AUSTIN, Texas and FREDERICK, Md., March 24, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced an expansi...
aTyr Pharma Proxy statement: Proxy Filing
aTyr Pharma filed a proxy statement on March 12, 2026, providing details for shareholder voting and corporate governance matters.
aTyr Pharma Transcript: Leerink Global Healthcare Conference 2026
Efzofitimod demonstrated strong trends in steroid reduction and significant, durable quality of life improvements in sarcoidosis, though the primary endpoint was not met due to high placebo response. The upcoming FDA meeting will clarify the regulatory path, while ongoing trials in scleroderma-related ILD show early promise.